{"paper_id":"7e44de25-fbf2-4af0-bd1e-56723a571b58","body_text":"Use of Continuous Oral Drospirenone for Menstrual Suppression in Adolescents\nAffiliations & Notes\naDepartment of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, Minnesota\nbDivision of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts\ncFrank H Netter School of Medicine at Quinnipiac University, North Haven, Connecticut\ndDepartment of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts\neDepartment of Surgery, Harvard Medical School, Boston, Massachusetts\nArticle Info\nPublication History:\nReceived March 15, 2024; Accepted September 4, 2024; Published online October 10, 2024\nFootnotes:\nConflicts of interest: The authors have no conflicts of interest to disclose.\nDOI: 10.1016/j.jadohealth.2024.09.004 External LinkAlso available on ScienceDirect External Link\nCopyright: © 2024 Society for Adolescent Health and Medicine. All rights are reserved, including those for text and data mining, AI training, and similar technologies.\nLinked Articles\nDownload started\nOkKeywords\nReferences\n1.\nCommittee on Clinical Consensus – Gynecology\nGeneral approaches to medical management of menstrual suppression: ACOG clinical consensus No. 3\nObstet Gynecol. 2022; 140:528-541\n2.\nDamm, T. ∙ Lamvu, G. ∙ Carrillo, J. ...\nContinuous vs. cyclic combined hormonal contraceptives for treatment of dysmenorrhea: A systematic review\nContracept X. 2019; 1, 100002\n3.\nEdelman, A. ∙ Micks, E. ∙ Gallo, M.F. ...\nContinuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception\nCochrane Database Syst Rev. 2014; 2014, CD004695\n4.\nCommittee on Adolescent Health Care\nDysmenorrhea and endometriosis in the adolescent\nObstet Gynecol. 2018; 132:e249-e258\n5.\nHee, L. ∙ Kettner, L.O. ∙ Vejtorp, M.\nContinuous use of oral contraceptives: An overview of effects and side-effects\nActa Obstet Gynecol Scand. 2013; 92:125-136\n6.\nAllen, R. ∙ Villavicencio, J.\nUnscheduled bleeding and contraceptive choice: Increasing satisfaction and continuation rates\nOpen Access J Contracept. 2016; 7:43-52\n7.\nRegidor, P.A. ∙ Colli, E. ∙ Georgiev, D. ...\nSafety, influence on the endometrium, sonographic changes and bleeding profile after 13 cycles with the new drospirenone only pill (DOP) for contraception\nHorm Mol Biol Clin Investig. 2021; 42:123-131\n8.\nApter, D. ∙ Colli, E. ∙ Gemzell-Danielsson, K. ...\nMulticenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase\nContraception. 2020; 101:412-419\n9.\nHillard, P.A.\nMenstrual suppression: Current perspectives\nInt J Womens Health. 2014; 6:631-637\n10.\nRobbins, C.L. ∙ Ott, M.A.\nContraception options and provision to adolescents\nMinerva Pediatr. 2017; 69:403-414\n11.\nTeal, S. ∙ Edelman, A.\nContraception selection, effectiveness, and adverse effects: A review\nJAMA. 2021; 326:2507\n12.\nCommittee on Adolescent Healthcare\nScreening and management of bleeding disorders in adolescents with heavy menstrual bleeding: ACOG Committee opinion number 785\nObstet Gynecol. 2019; 134:e71-e83\n13.\nCommittee on Adolescent Healthcare\nThe initial reproductive health visit: ACOG committee opinion summary, number 811\nObstet Gynecol. 2020; 136:868-869\n14.\nCommittee on Adolescence\nContraception for adolescents\nPediatrics. 2014; 134:e1244-e1256\n15.\nDuijkers, I.J.M. ∙ Heger-Mahn, D. ∙ Drouin, D. ...\nMaintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake\nContraception. 2016; 93:303-309\n16.\nde Melo, N.R.\nEstrogen-free oral hormonal contraception: Benefits of the progestin-only pill\nWomens Health. 2010; 6:721-735\n17.\nKebodeaux, C.A. ∙ Schwartz, B.I.\nExperience with intrauterine device insertion in never sexually active adolescents: A retrospective cohort study\nAm J Obstet Gynecol. 2018; 219:600.e1-600.e7\n18.\nKrattenmacher, R.\nDrospirenone: Pharmacology and pharmacokinetics of a unique progestogen\nContraception. 2000; 62:29-38\n19.\nBird, S.T. ∙ Pepe, S.R. ∙ Etminan, M. ...\nThe association between drospirenone and hyperkalemia: A comparative-safety study\nBMC Clin Pharmacol. 2011; 11:23\n20.\nSantos, M. ∙ Hendry, D. ∙ Sangi-Haghpeykar, H. ...\nRetrospective review of norethindrone use in adolescents\nJ Pediatr Adolesc Gynecol. 2014; 27:41-44\n21.\nMoreau, C. ∙ Cleland, K. ∙ Trussell, J.\nContraceptive discontinuation attributed to method dissatisfaction in the United States\nContraception. 2007; 76:267-272\n22.\nAhrendt, H.J. ∙ Adolf, D. ∙ Buhling, K.J.\nAdvantages and challenges of oestrogen-free hormonal contraception\nCurr Med Res Opin. 2010; 26:1947-1955\n23.\nArcher, D.F. ∙ Ahrendt, H.J. ∙ Drouin, D.\nDrospirenone-only oral contraceptive: Results from a multicenter noncomparative trial of efficacy, safety and tolerability\nContraception. 2015; 92:439-444\n24.\nStrowitzki, T. ∙ Kirsch, B. ∙ Elliesen, J.\nEfficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: An open-label, multicentre, randomised, controlled study\nJ Fam Plann Reprod Health Care. 2012; 38:94-101\n25.\nShim, J.Y. ∙ Garbo, G. ∙ Grimstad, F.W. ...\nUse of the drospirenone-only contraceptive pill in adolescents with endometriosis\nJ Pediatr Adolesc Gynecol. 2024; 37:402-406\n26.\nGrimstad, F. ∙ Kremen, J. ∙ Shim, J. ...\nBreakthrough bleeding in transgender and gender diverse adolescents and young adults on long-term testosterone\nJ Pediatr Adolesc Gynecol. 2021; 34:706-716\n27.\nBeksinska, M.E. ∙ Smit, J.A. ∙ Kleinschmidt, I. ...\nProspective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception\nContraception. 2010; 81:30-34\n28.\nExeltis Pharmaceuticals\nHighlights of prescribing information: Slynd (drospirenone)\nAvailable at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf\nDate: 2019\nDate accessed: October 28, 2022","source_license":"public-domain-us","license_restricted":false}